Abstract:Despite the great promises of sonodynamic therapy (SDT) in combination cancer therapy, its clinical applications are hindered by the lack of efficient sonosensitizers and "always‐on" pharmacological activities of therapeutic agents. Herein, we report the development of semiconducting polymers as efficient sonosensitizers and further development of sono‐immunotherapeutic nanobodies (SPNAb) for activatable cancer sono‐immunotherapy. Conjugation of anti‐CTLA‐4 antibodies onto the polymer nanoparticles through 1O2‐cleavable linker affords SPNAb with relatively low CTLA‐4 binding affinity. Upon sono‐irradiation, SPNAb generates 1O2 not only to elicit sonodynamic effect to induce the immunogenic cell death, but also to release anti‐CTLA‐4 antibodies and trigger in situ checkpoint blockade. Such a synergistic therapeutic action mediated by SPNAb modulates the tumoricidal function of T‐cell immunity by promoting the proliferation of cytotoxic T lymphocytes and depleting immunosuppressive regulatory T cells, resulting in effective tumor regression, metastasis inhibition, durable immunological memory, and prevention of relapse. Therefore, this study represents a proof‐of‐concept sonodynamic strategy using semiconducting polymers for precise spatiotemporal control over immunotherapy. This article is protected by copyright. All rights reserved

Activatable cancer sono‐immunotherapy using semiconducting polymer nanobodies